SCHEMBL251190

SCHEMBL251190

CCCCCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.65
TDP1 Q9NUW8 4/20 0.65
BLM P54132 2/20 0.65
PMP22 Q01453 2/20 0.65
ALOX15 P16050 2/20 0.65
KDM4E B2RXH2 1/20 0.65
LMNA P02545 1/20 0.65
CHRM2 P08172 1/20 0.65
ADRA2A P08913 1/20 0.65
DRD1 P21728 1/20 0.65
SLC6A2 P23975 1/20 0.65
SLC6A4 P31645 1/20 0.65
CYP2C19 P33261 1/20 0.65
ADRA1A P35348 1/20 0.65
DRD3 P35462 1/20 0.65
SLC6A3 Q01959 1/20 0.65
HRH3 Q9Y5N1 1/20 0.65
APP P05067 2/20 0.61
EYA2 O00167 1/20 0.61
ACE P12821 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11319897 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL11310530 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL8857559 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL11315528 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL8954314 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL8954395 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL3172648 0.98 TSHR (0.62) TSHRTDP1BLMPMP22ALOX15
SCHEMBL3477155 0.96 TDP1 (0.59) TSHRTDP1BLMPMP22ALOX15
SCHEMBL1976352 0.96 TSHR (0.56) TSHRTDP1BLMPMP22ALOX15
SCHEMBL19032432 0.94 TSHR (0.56) TSHRTDP1BLMPMP22ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1974720-B1 Use of a vitreoscilla filiformis lipopolysaccharide fraction as an agent for stimulating the synthesis of anti-microbial skin peptides OREAL (FR) 2013-02-13 EP claimed
US-20090035294-A1 LIPOPOLYSACCHARIDE FRACTIONS OF VITREOSCILLA FILIFORMIS USEFUL FOR STIMULATING THE SYNTHESIS OF ANTI-MICROBIAL PEPTIDES OF THE SKIN L'OREAL (FR) 2009-02-05 US claimed
US-20070059269-A1 Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer L'OREAL (FR) 2007-03-15 US claimed
US-20070015840-A1 Use of an alkyl ether of hydroxystilbene for the treatment of dry skin L'OREAL (FR) 2007-01-18 US claimed
EP-1413291-B1 Use of 5-Cholesten-3 beta,25-diol-7-one for the treatment of dry skin or scalp OREAL (FR) 2006-05-03 EP claimed
EP-1374850-B1 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride OREAL (FR) 2006-03-22 EP claimed
US-20040175342-A1 Process of making and using composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer L'OREAL (FR) 2004-09-09 US claimed
US-20040137023-A1 5-Cholesten-3beta, 25-diol-7-one, esters and ethers thereof, particularly for the treatment of dry skin and scalp L'OREAL (FR) 2004-07-15 US claimed
US-20030124161-A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer L'OREAL (FR) 2003-07-03 US claimed
EP-0629608-B1 Process for preparing N-acyl-N,N'N'-ethylenediaminetriacetic acid derivatives HAMPSHIRE CHEMICAL CORP (US) 1998-10-28 EP claimed
EP-0861827-A2 N-acyl-n,n'n'-ethylenediaminetriacetic acid derivatives and process for preparing the same HAMPSHIRE CHEMICAL CORPORATION (US) 1998-09-02 EP claimed
US-5621008-A TOPICAL DRUG FOR SKIN DISORDERS AVON PRODUCTS, INC. (US) 1997-04-15 US claimed
EP-0629608-A2 N-acyl-N,N'N'-ethylenediaminetriacetic acid derivatives and process for preparing same HAMPSHIRE CHEMICAL CORPORATION (US) 1994-12-21 EP claimed
WO-2024137567-A1 WET WIPE THE PROCTER & GAMBLE COMPANY (US) 2024-06-27 WO disclosed
US-12016944-B2 Mixtures comprising a protein extract for the treatment of human skin and/or hair SYMRISE AG (DE) 2024-06-25 US disclosed
US-11980679-B2 Sulfate free composition with enhanced deposition of scalp active THE PROCTER & GAMBLE COMPANY (US) 2024-05-14 US disclosed
US-5621008-A TOPICAL DRUG FOR SKIN DISORDERS AVON PRODUCTS, INC. (US) 1997-04-15 US disclosed
EP-0629608-A3 N-acyl-N,N'N'-ethylenediaminetriacetic acid derivatives and process for preparing same. HAMPSHIRE CHEMICAL CORP (US) 1995-06-28 EP disclosed
EP-0629608-A2 N-acyl-N,N'N'-ethylenediaminetriacetic acid derivatives and process for preparing same HAMPSHIRE CHEMICAL CORPORATION (US) 1994-12-21 EP disclosed
US-5284972-A N-acyl-N,N',N'-ethylenediaminetriacetic acid derivatives and process of preparing same HAMPSHIRE CHEMICAL CORP. (US) 1994-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070059269-A1 Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer DSG1, CUTA, DSC1 TSHR 4764/4885TDP1 2591/4885BLM 3456/4885
US-20090035294-A1 LIPOPOLYSACCHARIDE FRACTIONS OF VITREOSCILLA FILIFORMIS USEFUL FOR STIMULATING THE SYNTHESIS OF ANTI-MICROBIAL PEPTIDES OF THE SKIN CUTA, LRBA, LTA TSHR 1568/4885TDP1 4564/4885BLM 3867/4885
US-11980679-B2 Sulfate free composition with enhanced deposition of scalp active POLR1C, STS, DPM1 TSHR 3915/4885TDP1 966/4885BLM 3870/4885
US-20040137023-A1 5-Cholesten-3beta, 25-diol-7-one, esters and ethers thereof, particularly for the treatment of dry skin and scalp CYP46A1, HSD3B1, DHCR7 TSHR 3771/4885TDP1 782/4885BLM 2382/4885
US-20070015840-A1 Use of an alkyl ether of hydroxystilbene for the treatment of dry skin CYP8B1, HSD17B11, HSD17B1 TSHR 2043/4885TDP1 1732/4885BLM 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.